Search Results - "Cahill, Katherine"

Immunologic effects of aspirin desensitization and high-dose aspirin therapy in aspirin-exacerbated respiratory disease by Cahill, Katherine N.

“…The clinical benefits of high-dose (325-1300 mg daily) aspirin therapy in AERD are well established and have been recently summarized by Stevens et al.1 Here,…”
Get full text

Fevipiprant in CRSwNP and comorbid asthma: Wrong target population or wrong PGD2 receptor? by Cahill, Katherine N.

Get full text

Prostaglandin D2 : A dominant mediator of aspirin-exacerbated respiratory disease by Cahill, Katherine N., MD, Bensko, Jillian C, Boyce, Joshua A., MD, Laidlaw, Tanya M., MD

“…Background Aspirin desensitization followed by high-dose aspirin therapy is routinely performed for patients with aspirin-exacerbated respiratory disease…”
Get full text

Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists by Foer, Dinah, Beeler, Patrick E, Cui, Jing, Karlson, Elizabeth W, Bates, David W, Cahill, Katherine N

“…GLP-1R (glucagon-like peptide-1 receptor) agonists are approved to treat type 2 diabetes mellitus and obesity. GLP-1R agonists reduce airway inflammation and…”
Get full text

Allergic inflammatory memory in human respiratory epithelial progenitor cells by Ordovas-Montanes, Jose, Dwyer, Daniel F., Nyquist, Sarah K., Buchheit, Kathleen M., Vukovic, Marko, Deb, Chaarushena, Wadsworth, Marc H., Hughes, Travis K., Kazer, Samuel W., Yoshimoto, Eri, Cahill, Katherine N., Bhattacharyya, Neil, Katz, Howard R., Berger, Bonnie, Laidlaw, Tanya M., Boyce, Joshua A., Barrett, Nora A., Shalek, Alex K.

“…Barrier tissue dysfunction is a fundamental feature of chronic human inflammatory diseases 1 . Specialized subsets of epithelial cells—including secretory and…”
Get full text

Mechanistic and clinical updates in AERD: 2021-2022 by Stevens, Whitney W., Cahill, Katherine N.

“…Aspirin-exacerbated respiratory disease (AERD) is a unique and often clinically severe disease affecting a subgroup of adults with asthma and chronic…”
Get full text

Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352 by Foer, Dinah, Cahill, Katherine N.

Get full text

Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease by Cahill, Katherine N., MD, Boyce, Joshua A., MD

“…The clinical benefit of the 5-lypoxygenase inhibitor zileuton on basal respiratory symptoms, as well as its ability to shift the dose of aspirin needed to…”
Get full text

Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease by Buchheit, Kathleen M., MD, Cahill, Katherine N., MD, Katz, Howard R., PhD, Murphy, Katherine C., BA, Feng, Chunli, MD, Lee-Sarwar, Kathleen, MD, Lai, Juying, MD, Bhattacharyya, Neil, MD, Israel, Elliot, MD, Boyce, Joshua A., MD, Laidlaw, Tanya M., MD

“…Background Prostaglandin (PG) D2 is the dominant COX product of mast cells and is an effector of aspirin-induced respiratory reactions in patients with…”
Get full text

Impact of Antihyperglycemic Drugs on Asthma Outcomes: Diversifying the Research Portfolio by Wu, Tianshi David, Cahill, Katherine N.

Get full text

Glucagon‐like peptide‐1 receptor agonist inhibits aeroallergen‐induced activation of ILC2 and neutrophilic airway inflammation in obese mice by Toki, Shinji, Newcomb, Dawn C., Printz, Richard L., Cahill, Katherine N., Boyd, Kelli L., Niswender, Kevin D., Peebles, R. Stokes

“…Background Obesity is a risk factor for the development of asthma. However, pharmacologic therapeutic strategies that specifically target obese asthmatics have…”
Get full text

The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology by Stevens, Whitney W., Jerschow, Elina, Baptist, Alan P., Borish, Larry, Bosso, John V., Buchheit, Kathleen M., Cahill, Katherine N., Campo, Paloma, Cho, Seong H., Keswani, Anjeni, Levy, Joshua M., Nanda, Anil, Laidlaw, Tanya M., White, Andrew A.

“…Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance…”
Get full text

Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial by Cahill, Katherine N, Cui, Jing, Kothari, Parul, Murphy, Katherine, Raby, Benjamin A, Singer, Joseph, Israel, Elliot, Boyce, Joshua A, Laidlaw, Tanya M

“…Daily high-dose aspirin therapy benefits many patients with aspirin-exacerbated respiratory disease but provides no benefit for aspirin-tolerant patients with…”
Get full text

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma by Cahill, Katherine N, Katz, Howard R, Cui, Jing, Lai, Juying, Kazani, Shamsah, Crosby-Thompson, Allison, Garofalo, Denise, Castro, Mario, Jarjour, Nizar, DiMango, Emily, Erzurum, Serpil, Trevor, Jennifer L, Shenoy, Kartik, Chinchilli, Vernon M, Wechsler, Michael E, Laidlaw, Tanya M, Boyce, Joshua A, Israel, Elliot

“…This proof-of-principle trial showed that imatinib treatment reduced mast-cell activation and improved airway responsiveness in patients with severe refractory…”
Get full text

Inflammatory heterogeneity in aspirin-exacerbated respiratory disease by Scott, William C., Cahill, Katherine N., Milne, Ginger L., Li, Ping, Sheng, Quanhu, Huang, Li Ching, Dennis, Spencer, Snyder, Jacob, Bauer, Ashley M., Chandra, Rakesh K., Chowdhury, Naweed I., Turner, Justin H.

“…Aspirin-exacerbated respiratory disease (AERD) is a mechanistically distinct subtype of chronic rhinosinusitis with nasal polyps (CRSwNP). Although frequently…”
Get full text

Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes by Foer, Dinah, Strasser, Zachary H, Cui, Jing, Cahill, Katherine N, Boyce, Joshua A, Murphy, Shawn N, Karlson, Elizabeth W

“…Patients with chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2D) have worse clinical outcomes compared with patients without metabolic…”
Get full text

Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease by Cahill, Katherine N., Murphy, Katherine, Singer, Joseph, Israel, Elliot, Boyce, Joshua A., Laidlaw, Tanya M.

“…Plasma tryptase elevation during aspirin-induced respiratory reactions occurs in 50% of reactions despite CysLT 1 R antagonist prophylaxis and identifies lung…”
Get full text

Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs by Laidlaw, Tanya M., MD, Cahill, Katherine N., MD

“…Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the most common culprits of drug-induced hypersensitivity reactions, and can lead to a…”
Get full text

A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease by DeGregorio, Geneva A., Singer, Joseph, Cahill, Katherine N., Laidlaw, Tanya

“…Aspirin challenge and desensitization remains the criterion standard in diagnosis and treatment for patients with aspirin-exacerbated respiratory disease…”
Get full text

Objective validity of patient‐reported symptoms in aspirin‐exacerbated respiratory disease patients by Patel, Pooja P., Cui, Jing, Cahill, Katherine N., Laidlaw, Tanya M.

Get full text